FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 295:1337-1343 December 9, 1976 Number 24 Next

	Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited

Abstract

To evaluate their role as a form of replacement therapy, frozen irradiated red blood cells were administered to a child with adenosine deaminase deficiency associated with severe combined immunodeficiency disease. In vitro lymphocyte responses to mitogens and allogeneic cells were restored. Subsequently, a "thymus shadow" appeared, and immunoglobulin synthesis was demonstrated. Frozen irradiated plasma, which alone had no effect on lymphocytes numbers or responses, promoted lymphocytosis when given with frozen irradiated red blood cells. The patient received the transfusions with or without irradiated plasma at four-week intervals and remained free of infection for 17 months. The patient's lymphocyte adenosine triphosphate levels were elevated before therapy, which consistently reduced them without altering the lymphocyte adenosine deaminase activity. Enzyme replacement therapy may provide a way to treat patients with adenosine deaminase deficiency associated with severe combined immunodeficiency disease who do not have histocompatible bone-marrow donors.

This article has been cited by other articles:

• Honig, M., Albert, M. H., Schulz, A., Sparber-Sauer, M., Schutz, C., Belohradsky, B., Gungor, T., Rojewski, M. T., Bode, H., Pannicke, U., Lippold, D., Schwarz, K., Debatin, K.-M., Hershfield, M. S., Friedrich, W. (2007). Patients with adenosine deaminase deficiency surviving after hematopoietic stem cell transplantation are at high risk of CNS complications. Blood 109: 3595-3602 [Abstract] [Full Text]  
• Marwaha, V. R., Italia, D. H., Esper, F., Hostoffer, R. W. (2000). Extreme T hrombocytosis in Response to PEG-ADA: Early Therapeutic and Risk Indicator. CLIN PEDIATR 39: 183-186  
• Bordignon, C., Notarangelo, L. D., Nobili, N., Ferrari, G., Casorati, G., Panina, P., Mazzolari, E., Maggioni, D., Rossi, C., Servida, P., Ugazio, A. G., Mavilio, F. (1995). Gene Therapy in Peripheral Blood Lymphocytes and Bone Marrow for ADA- Immunodeficient Patients. Science 270: 470-475 [Abstract]  
• Blaese, R. M., Culver, K. W., Miller, A. D., Carter, C. S., Fleisher, T., Clerici, M., Shearer, G., Chang, L., Chiang, Y., Tolstoshev, P., Greenblatt, J. J., Rosenberg, S. A., Klein, H., Berger, M., Mullen, C. A., Ramsey, W. J., Muul, L., Morgan, R. A., Anderson, W. F. (1995). T Lymphocyte-Directed Gene Therapy for ADA- SCID: Initial Trial Results After 4 Years. Science 270: 475-480 [Abstract]  
• Nelson, D.L., Chang, S.M.W., Henkel-Tigges, J., Wager-Smith, K., Belmont, J.W., Caskey, C.T. (1986). Gene Replacement Therapy for Inborn Errors of Purine Metabolism. Cold Spring Harb Symp Quant Biol 51: 1065-1071 [Abstract]  
• MITCHELL, B. S., KELLEY, W. N. (1980). Purinogenic Immunodeficiency Diseases: Clinical Features and Molecular Mechanisms. ANN INTERN MED 92: 826-831 [Abstract]  
• Yulish, B. S., Stern, R. C., Polmar, S. H. (1980). Partial Resolution of Bone Lesions: A Child With Severe Combined Immunodeficiency Disease and Adenosine Deaminase Deficiency After Enzyme-Replacement Therapy. Arch Pediatr Adolesc Med 134: 61-63 [Abstract]  
• ALLERGY AND IMMUNOLOGY COMMITTEE, (1979). Allergy and Immunology: An Annotated Bibliography of Recent Literature: References to Journal Articles and Other Papers. ANN INTERN MED 90: 135-139 [Abstract]  
• Hershfield, M., Krodich, N. (1978). S-adenosylhomocysteine hydrolase is an adenosine-binding protein: a target for adenosine toxicity. Science 202: 757-760 [Abstract]  
• Hershfield, M., Snyder, F., Seegmiller, J. (1977). Adenine and adenosine are toxic to human lymphoblast mutants defective in purine salvage enzymes. Science 197: 1284-1287 [Abstract]